The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
More top news
Warmer - even without wall to wall blue skies
The telecoms company announced a 9% rise in profits after increasing prices for TV and broadband customers.
Millions of voters headed to the polls to vote in today's local elections. Here is when the results are expected in.